Sequenom shares oversold at current levels, says Maxim Maxim says Sequenom (SQNM) shares are oversold following the acquisition of competitor Verinata by Illumina (ILMN) and Verinata's partnership with PerkinElmer (PKI). The firm believes remains Sequenom remains well positioned for long-term growth and reiterates a Buy rating on the stock.
News For SQNM From The Last 14 Days
Check below for free stories on SQNM the last two weeks.